Prakash Achaary

CANTON, Mich. (March 19, 2025) – MMS, an award-winning, data-focused clinical research organization (CRO), is showcasing its expansion as a tech-enabled, full-service Risk Evaluation and Mitigation Strategies (REMS) solutions provider today during a presentation given by CEO Dr. Uma Sharma at the REMS Industry Consortium (RIC) Annual Meeting today in Arlington, Virginia. The integration of … MMS REMS-focused Technology bolsters Full-Service REMS Solutions

CANTON, Mich. (February 12, 2025) – MMS, an award-winning, data-focused clinical research organization (CRO), announced today its acquisition of Exploristics, a leading biostatistics and data science company based in Belfast, Northern Ireland. The acquisition will add the company’s flagship product, KerusCloud®, a state-of-the-art, cloud-based statistical modeling and simulation platform to MMS’ data-driven approach towards efficient … MMS Acquires Exploristics and KerusCloud Simulation Platform to Expand Biostatistics and Data Science Capabilities as a Global Data-Focused CRO

The Biennial Scientific Symposium at MMS is a global opportunity to bring together leading minds from within the CRO and across the industry to explore the intersection of artificial intelligence (AI) in pharma, innovative trial designs, and leadership in a tech-enabled world. Over the course of four days, thought leaders, scientists, and industry experts shared … AI in Pharma and Innovative Leadership Were on Display at the Biennial MMS Scientific Symposium

DETROIT (November 19, 2024) – MMS, a leading data and regulatory focused clinical research organization (CRO), today announced its recognition as a Top Workplace by the Detroit Free Press and the USA Today Network for the fourth consecutive year. This prestigious award is based entirely on employee feedback, highlighting the company’s unwavering commitment to fostering … MMS Recognized as a Top Workplace by Detroit Free Press and USA Today Network for the Fourth Consecutive Year

CANTON, Mich. (November 8, 2024) – MMS, a leading data and regulatory focused clinical research organization (CRO), today announced that its regulatory team has been selected as one of three top finalists in the Fierce CRO Awards for Leadership in Regulatory Compliance. The Fierce CRO Awards aim to recognize and celebrate the remarkable achievements of … MMS Named a Finalist in the 2024 Fierce CRO Awards for Leadership in Regulatory Compliance

CANTON, Mich. (October 15, 2024) – MMS, a leading data and regulatory focused clinical research organization (CRO), today announced that it has been awarded bronze medal status by EcoVadis, demonstrating its commitment to environmental, social, and governance (ESG) initiatives. Bronze medal status is earned by organizations that are in the top 35th  percentile globally when … MMS Recognized with EcoVadis Bronze Medal for Leadership in ESG Sustainability Efforts as a Leading Clinical Research Organization (CRO)

CANTON, Mich. and READING, UK (July 17, 2024) – MMS, a data-focused clinical research organization (CRO), announced today that Ben Dudley has been appointed as the company’s new Chief Commercial Officer (CCO). Based in the UK, Ben Dudley brings more than 25 years of life sciences expertise on the CRO and Sponsor side, holding previous operational … Industry Veteran Ben Dudley Joins MMS as Chief Commercial Officer (CCO) to Drive Continued Growth for the Data-focused Clinical Research Organization

CANTON, Michigan, and LONDON (April 4, 2024) – MMS, a leading, data-focused clinical research organization (CRO), announced today that the company has expanded its biometrics leadership within European operations by hiring James Zee as Director of Global Statistical Programming. Based in the United Kingdom (UK), Zee brings 25 years of experience across several leading pharmaceutical companies, … MMS Hires Pharmaceutical Industry Veteran James Zee for Global Biometrics Leadership in Europe Amid Strong Regional Growth

Canton, Mich. (March 5, 2024) –MMS Holdings Inc, a distinguished global Clinical Research Organization (CRO), stands at the forefront of supporting pharmaceutical and biotech companies, along with numerous smaller enterprises, across a comprehensive range of services. With an impressive track record of successfully completing over 50 submissions for drug approval in the past five years, MMS … MMS Holdings Inc – A Data-Centric CRO Powerhouse Reshaping Drug Development on a Global Scale

Canton, Mich. (December 13, 2023) – MMS, a data-focused Clinical Research Organization (CRO), announced Lykos Therapeutics, formerly known as MAPS Public Benefit Corporation (MAPS PBC) submitted a New Drug Application (NDA) to the FDA for MDMA (midomafetamine capsules) used in combination with psychological intervention, which includes psychotherapy, or talk therapy, and other supportive services provided by a qualified … MMS Supported Lykos Therapeutics: NDA Submitted to FDA for First Psychedelic-Assisted Therapy for PTSD

LONDON (18 April 2023) – MMS Holdings, a data-focused contract research organization (CRO), has been named a Great Place to Work-Certified™ organization in the UK. This comes as the number of MMS colleagues based in the UK has doubled in just one year. “We are proud to be certified as a Great Place to Work in … MMS Named Great Place to Work in the UK as Growth in the Region Doubles

CANTON, Mich. (March 21, 2023) – MMS Holdings, an award-winning, data-focused CRO, announced today the addition of Dr. Philip Breitfeld and Dr. Bernhardt Zeiher to its board of scientific advisors. Both industry leaders in innovative clinical trial delivery solutions, Dr. Breitfeld and Dr. Zeiher’s additions as advisors expand MMS’ therapeutic area expertise to support growth in … MMS Scientific Advisory Board’s New Members Expand CRO’s Therapeutic Expertise